To assess the ability of antigen presentation in gliomas, we first explored the expression of the major histocompatibility complex class I. As shown in Figure 3A, no significant difference in the expression levels of HLA-A, B, or C was found between HMP and NHMP samples in either IDH-mutant or IDH-wildtype tumors. Here, HLA-A is linked to central nervous system cancer.